MultiMetaVerse Holdings Limited - Ordinary Shares 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 15, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Entity File Number	001-40318
Entity Registrant Name	MODEL PERFORMANCE ACQUISITION CORP
Entity Incorporation, State or Country Code	D8
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	Cheung Kong Center,
Entity Address, Address Line Two	58th Floor
Entity Address, Address Line Three	2 Queen’s Road Central
Entity Address, City or Town	Central
Entity Address, Country	HK
Entity Address, Postal Zip Code	5801
City Area Code	852
Local Phone Number	9258 9728
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Central Index Key	0001841993
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Units, each consisting of one Class A ordinary share, with no par value
Document Information [Line Items]
Title of 12(b) Security	Units, each consisting of one Class A ordinary share, with no par value, one-half of one redeemable warrant
Trading Symbol	MPACU
Security Exchange Name	NASDAQ
Class A ordinary shares
Document Information [Line Items]
Title of 12(b) Security	Class A ordinary shares included as part of the units
Trading Symbol	MPAC
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		6,100,000
Redeemable warrants included as part
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants included as part of the units
Trading Symbol	MPACW
Security Exchange Name	NASDAQ
Rights included as part of the units
Document Information [Line Items]
Title of 12(b) Security	Rights included as part of the units
Trading Symbol	MPACR
Security Exchange Name	NASDAQ
Class B ordinary shares
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		1,437,500

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Assets
Cash	$ 552,084	$ 336,852
Prepaid expenses and other current assets	269,811	49,253
Total current assets	821,895	386,105
Marketable securities held in Trust Account	59,308,721	58,078,580
Total Assets	60,130,616	58,464,685
Liabilities and Shareholders' Deficit
Accrued offering costs and expenses	455,195	559,478
Due to related parties	5,413	58,413
Promissory note - MMV	2,459,975
Total current liabilities	2,920,583	617,891
Warrant liability	15,443	52,151
Deferred underwriting fee	2,012,500	2,012,500
Total liabilities	4,948,526	2,682,542
Commitments and Contingency (Note 8)
Class A ordinary shares subject to possible redemption, 5,750,000 shares at $10.30 and $10.10 redemption value as of June 30, 2022 and December 31, 2021 respectively	59,308,721	58,078,580
Shareholders' Deficit:
Preference shares, no par value; 1,000,000 shares authorized; none issued and outstanding
Accumulated deficit	(7,076,632)	(5,246,438)
Total shareholders' deficit	(4,126,631)	(2,296,437)
Total Liabilities and Shareholders' Deficit	60,130,616	58,464,685
Class A ordinary shares
Shareholders' Deficit:
Common stock	2,925,000	2,925,000
Class B ordinary shares
Shareholders' Deficit:
Common stock	$ 25,001	$ 25,001

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, par value, (per share)	$ 0	$ 0
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class A ordinary shares
Common shares, par value, (per share)	$ 0	$ 0
Common shares, shares authorized	100,000,000	100,000,000
Common shares, shares issued	350,000	350,000
Common shares, shares outstanding	350,000	350,000
Class B ordinary shares
Common shares, par value, (per share)	$ 0	$ 0
Common shares, shares authorized	10,000,000	10,000,000
Common shares, shares issued	1,437,500	1,437,500
Common shares, shares outstanding	1,437,500	1,437,500
Class A Common Stock Subject to Redemption
Common stock subject to possible redemption, shares	5,750,000	5,750,000
Common stock subject to possible redemption, redemption value	$ 10.30	$ 10.10

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Formation and operating costs	$ 530,365	$ 127,252	$ 716,902	$ 130,977
Loss from operations	(530,365)	(127,252)	(716,902)	(130,977)
Other income
Change in fair value of warrant liability	6,612	61,263	36,708	61,263
Trust interest income	78,708	668	80,141	668
Total other income	85,320	61,931	116,849	61,931
Net loss	$ (445,045)	$ (65,321)	$ (600,053)	$ (69,046)
Class A Common Stock Subject to Redemption
Other income
Weighted average shares outstanding, Basic (in shares)	5,750,000	4,967,033	5,750,000	2,612,717
Weighted average shares outstanding, Diluted (in shares)	5,750,000	4,967,033	5,750,000	2,612,717
Net income (loss) per share, basic	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)
Net income (loss) per share, diluted	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)
Class B and Non-redeemable Class A
Other income
Weighted average shares outstanding, Basic (in shares)	1,787,500	1,740,357	1,787,500	1,555,260
Weighted average shares outstanding, Diluted (in shares)	1,787,500	1,740,357	1,787,500	1,555,260
Net income (loss) per share, basic	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)
Net income (loss) per share, diluted	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($)	Class A ordinary shares Common Stock Private Placement	Class A ordinary shares Common Stock Over-allotment option	Class A ordinary shares Common Stock	Class B ordinary shares Common Stock	Accumulated Deficit Over-allotment option	Accumulated Deficit	Private Placement	Over-allotment option	Total
Balance at the beginning balance at Jan. 07, 2021			$ 0	$ 0		$ 0			$ 0
Balance as of beginning balance (in shares) at Jan. 07, 2021			0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Founder shares				$ 25,001					25,001
Issuance of Founder shares (in shares)				1,437,500
Net loss						(3,725)			(3,725)
Balance at the ending balance at Mar. 31, 2021				$ 25,001		(3,725)			21,276
Balance as of ending balance (in shares) at Mar. 31, 2021				1,437,500
Balance at the beginning balance at Jan. 07, 2021			$ 0	$ 0		0			0
Balance as of beginning balance (in shares) at Jan. 07, 2021			0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion of interest income									(668)
Net loss									(69,046)
Balance at the ending balance at Jun. 30, 2021			$ 2,925,000	$ 25,001		(4,440,454)			1,490,453
Balance as of ending balance (in shares) at Jun. 30, 2021			350,000	1,437,500
Balance at the beginning balance at Jan. 07, 2021			$ 0	$ 0		0			0
Balance as of beginning balance (in shares) at Jan. 07, 2021			0	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion of carrying value to redemption value									(4,257,708)
Additional amount in deposited into trust ($10.10 per Unit-$10.00 per Unit)									(575,000)
Balance at the ending balance at Dec. 31, 2021			$ 2,925,000	$ 25,001		(5,246,438)			(2,296,437)
Balance as of ending balance (in shares) at Dec. 31, 2021			350,000	1,437,500
Balance at the beginning balance at Mar. 31, 2021				$ 25,001		(3,725)			21,276
Balance as of beginning balance (in shares) at Mar. 31, 2021				1,437,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Additional amount deposited into trust ($0.10 per Class A ordinary share subject to possible redemption)						(575,000)			(575,000)
Sale of private placement units	$ 2,700,000	$ 225,000					$ 2,700,000	$ 225,000
Sale of private placement units (in shares)	270,000	22,500					270,000	22,500
Issuance of representative shares					$ 60,257	401,711		$ 60,257	401,711
Issuance of representative shares (in shares)		7,500	50,000
Accretion of carrying value to redemption value						(4,257,708)			(4,257,708)
Accretion of interest income						(668)			(668)
Net loss						(65,321)			(65,321)
Balance at the ending balance at Jun. 30, 2021			$ 2,925,000	$ 25,001		(4,440,454)			1,490,453
Balance as of ending balance (in shares) at Jun. 30, 2021			350,000	1,437,500
Balance at the beginning balance at Dec. 31, 2021			$ 2,925,000	$ 25,001		(5,246,438)			(2,296,437)
Balance as of beginning balance (in shares) at Dec. 31, 2021			350,000	1,437,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Remeasurement of Class A ordinary shares subject to possible redemption						(1,433)			(1,433)
Additional amount deposited into trust ($0.10 per Class A ordinary share subject to possible redemption)						(575,000)			(575,000)
Net loss						(155,008)			(155,008)
Balance at the ending balance at Mar. 31, 2022			$ 2,925,000	$ 25,001		(5,977,879)			(3,027,878)
Balance as of ending balance (in shares) at Mar. 31, 2022			350,000	1,437,500
Balance at the beginning balance at Dec. 31, 2021			$ 2,925,000	$ 25,001		(5,246,438)			(2,296,437)
Balance as of beginning balance (in shares) at Dec. 31, 2021			350,000	1,437,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of private placement units (in shares)							270,000
Accretion of carrying value to redemption value									(4,257,708)
Accretion of interest income									(80,141)
Additional amount in deposited into trust ($10.10 per Unit-$10.00 per Unit)									(1,725,000)
Net loss									(600,053)
Balance at the ending balance at Jun. 30, 2022			$ 2,925,000	$ 25,001		(7,076,632)			$ (4,126,631)
Balance as of ending balance (in shares) at Jun. 30, 2022			350,000	1,437,500					57,500
Balance at the beginning balance at Mar. 31, 2022			$ 2,925,000	$ 25,001		(5,977,879)			$ (3,027,878)
Balance as of beginning balance (in shares) at Mar. 31, 2022			350,000	1,437,500
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Remeasurement of Class A ordinary shares subject to possible redemption						(78,708)			(78,708)
Additional amount deposited into trust ($0.10 per Class A ordinary share subject to possible redemption)						(575,000)			(575,000)
Accretion of interest income									(78,708)
Net loss						(445,045)			(445,045)
Balance at the ending balance at Jun. 30, 2022			$ 2,925,000	$ 25,001		$ (7,076,632)			$ (4,126,631)
Balance as of ending balance (in shares) at Jun. 30, 2022			350,000	1,437,500					57,500

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT (Parenthetical) - $ / shares		3 Months Ended	6 Months Ended
	Apr. 15, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 29, 2022	Mar. 31, 2022	Mar. 29, 2022
Class A ordinary share subject to possible redemption, per share		$ 10	$ 0.10	$ 0.10	$ 0.10	$ 0.10
Temporary Equity, Redemption Price Per Share		$ 10.10
Private Placement
Number of units sold	22,500	270,000	270,000
Over-allotment option
Number of units sold	750,000	22,500

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (600,053)	$ (69,046)
Adjustments to reconcile net loss to net cash used in operating activities:
Formation costs paid by Sponsor	0	3,725
Interest earned on cash and marketable securities held in Trust Account	(80,141)	(668)
Change in fair value of warrant liability	(36,708)	(61,263)
Changes in current assets and liabilities:
Prepaid assets	(220,558)	5,664
Due to Related Party	53,000	(26,333)
Accrued expenses	(104,283)	27,865
Net cash used in operating activities	(1,094,743)	(67,390)
Cash flows from investing activities:
Amount deposited into trust	(1,150,000)	(58,075,000)
Net cash used in investing activities	(1,150,000)	(58,075,000)
Cash flows from financing activities:
Proceeds from loan from related party	2,459,975	0
Proceeds from initial public offering, net of costs	0	56,350,000
Proceeds from private placement	0	2,925,000
Payment of deferred offering costs	0	(317,750)
Net cash provided by financing activities	2,459,975	58,957,250
Net change in cash	215,232	814,860
Cash, beginning of the period	336,852	0
Cash, end of the period	552,084	814,860
Supplemental disclosure of non-cash investing and financing activities
Offering costs paid by Sponsor in exchange for issuance of ordinary shares	0	25,001
Offering costs paid by Sponsor under promissory note	0	153,518
Deferred underwriting discount	0	2,012,500
Initial classification of private warrants	0	136,971
Initial value of Class A ordinary shares subject to possible conversion	0	50,500,000
Remeasurement of Class A ordinary shares subject to possible redemption	$ 80,141	$ 7,236,640

Organization, Business Operatio

Organization, Business Operation, Liquidation and Going Concern	6 Months Ended
	Jun. 30, 2022
Organization, Business Operation, Liquidation and Going Concern
Organization, Business Operation, Liquidation and Going Concern	Note 1 — Organization, Business Operation, Liquidation and Going Concern Model Performance Acquisition Corp. (the “Company”) was incorporated as a British Virgin Islands business company on January 8, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”). As of June 30, 2022, the Company had not commenced any operations. All activity for the period from January 8, 2021 (inception) through June 30, 2022 relates to the Company’s formation and the initial public offering (“IPO”), which is described below, and subsequent to the IPO, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is First Euro Investments Limited, a British Virgin Islands company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on April 7, 2021 (the “Effective Date”). On April 12, 2021, the Company consummated the IPO of 5,000,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “public share”), at $10.00 per Unit, generating gross proceeds of $50,000,000, which is discussed in Note 4. Simultaneously with the closing of the IPO, the Company consummated the sale of 270,000 units (the “Private Placement”), at a price of $10.00 per Private Unit, which is discussed in Note 5. On April 15, 2021, the underwriters exercised the over-allotment option in full and purchased an additional 750,000 Units (the “Over-Allotment Units”), generating gross proceeds of $7,500,000. In connection with the closing of the purchase of the Over-Allotment Units, the Company sold an additional 22,500 Private Placement Units, generating gross proceeds of $225,000. Transaction costs of the IPO and the exercise of over-allotment option, amounted to $4,120,737 consisting of $1,150,000 of underwriting fee, $2,012,500 of deferred underwriting fee, $496,269 of other offering costs, and $461,968 of fair value of 57,500 representative’s ordinary shares. Following the closing of the IPO and the exercise of over-allotment option, $58,075,000 ($10.10 per Unit) from the net offering proceeds of the sale of the Units in the IPO, the sale of the Private Placement and the exercise of over-allotment option was placed in a trust account (the “Trust Account”) and invested in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any, the proceeds from the IPO and the sale of the Private Placement Units will not be released from the Trust Account until the earliest of (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Company’s amended and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 12 months from the closing of the IPO (or up to 18 months from the closing of the IPO if the Company extends the period of time to consummate a Business Combination by the full amount of time) or (B) with respect to any other provision relating to shareholders’ rights or pre-Business Combination activity and (iii) the redemption of all of the public shares if the Company is unable to complete the initial Business Combination within 12 months from the closing of the IPO (or up to 18 months from the closing of the IPO if the Company extends the period of time to consummate a Business Combination by the full amount of time), subject to applicable law. On March 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to July 12, 2022. On June 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from July 12, 2022 to October 12, 2022. Merger The Company has entered into a merger agreement, dated as of August 6, 2021 (the “Merger Agreement”), which provides for a business combination between the Company and MultiMetaVerse Inc., a Cayman Islands exempted company (“MMV”). Pursuant to the Merger Agreement, the business combination will be effected in two steps: (i) subject to the approval and adoption of the Merger Agreement by the shareholders of the Company, the Company will reincorporate to British Virgin Islands by merging with and into Model Performance Mini Corp., a British Virgin Islands business company (“PubCo”), with PubCo remaining as the surviving publicly traded entity (the “Reincorporation Merger”); and (ii) Model Performance Mini Sub Corp., a Cayman Islands exempted company and wholly-owned subsidiary of PubCo (“Merger Sub”), will be merged with and into MMV resulting in MMV being a wholly-owned subsidiary of PubCo (the “Acquisition Merger”). On January 6, 2022, each of the parties to the Merger Agreement and Avatar Group Holdings Limited entered into a First Amendment to the Merger Agreement (the “Amendment”). Under the Amendment, the proposed business combination (the “Business Combination”) will be extended to September 30, 2022 from December 31, 2021. The Amendment includes an amended covenant to procure equity financing in the aggregate amount of $10,000,000 no later than fifteen (15) days prior to the closing date of the Business Combination. The Amendment also contains five (5) new covenants. Simultaneously, MMV agrees to make to Company, and the Company agrees to borrow from MMV three tranches of non-interest bearing loans in the aggregate principal amount of $2,750,000, all of which shall become repayable upon closing of the Business Combination, or if the Company, Model Performance Mini Corp. and Model Performance Mini Sub Corp. materially breach the Merger Agreement or the Amendment and such breach has not been cured within fifteen (15) days after the Company’s receipt of such notice containing the details of breach. On January 10, 2022, March 21, 2022, June 21, 2022 and June 29, 2022, the Company received loans for an aggregate of $2,459,975, from the target company, MMV. Simultaneously, the Company has entered into certain subscription agreement (the “Subscription Agreement”) with certain investor, pursuant to which such investor has committed to provide equity financing to the Company immediately prior to the closing of the business combination in the aggregate amount of $10,000,000 (the “Committed PIPE Financing”). As soon as practicable after the signing, but in any event no later than 15 days prior to the closing of the business combination, the MMV shall procure additional reputable investors to provide equity financing in the aggregate amount of $10,000,000 to the Company on substantially the same terms and conditions in the Subscription Agreement (the “Additional PIPE Financing”, together with the Committed PIPE Financing, the “Equity Financing”). Liquidity, Capital Resources and Going Concern As of June 30, 2022, the Company had $552,084 in cash, and working capital deficiency of $2,098,688. The Company’s liquidity needs prior to the consummation of the IPO were satisfied through the proceeds of $200,000 under the Note (Note 6). Subsequent from the consummation of the IPO, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the IPO and the Private Placement held outside of the Trust Account. On January 10, 2022, March 21, 2022, June 21, 2022 and June 29, 2022, the Company received loans for an aggregate of $2,459,975, from MMV. The Company has incurred and expect to continue to incur significant costs in pursuit of the acquisition plans. If the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the Business Combination. Moreover, the Company may need to obtain additional financing or draw on the Working Capital Loans (as defined below) either to complete a Business Combination or because it becomes obligated to redeem a significant number of the public shares upon consummation of the Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of the Business Combination. If the Company is unable to complete the Business Combination because it does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. In addition, following the Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet the obligations. In addition, in connection with the assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” the Company has until October 12, 2022 (after two extensions for a quarter each since April 12, 2022, the initial expiration date) to consummate the proposed Business Combination. It is uncertain that the Company will be able to consummate the proposed Business Combination by this time. Management has determined that the mandatory liquidation, should a business combination not occur, and potential subsequent dissolution, raises substantial doubt about the ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after October 12, 2022. On August 6, 2021, the Company entered into a Merger Agreement, which provides for a business combination between the Company and MMV. The Company intend to complete the proposed Business Combination before the mandatory liquidation date. However, there can be no assurance that the Company will be able to consummate any business combination by October 12, 2022. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Risks and Uncertainties On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. The impact of the COVID-19 outbreak on the Company’s financial position will depend on future developments, including the duration and spread of the outbreak and related advisories and restrictions. These developments and the impact of the COVID-19 outbreak on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s financial position may be materially adversely affected. Additionally, the Company’s ability to complete an initial Business Combination may be materially adversely affected due to significant governmental measures being implemented to contain the COVID-19 outbreak or treat its impact, including travel restrictions, the shutdown of businesses and quarantines, among others, which may limit the Company’s ability to have meetings with potential investors or affect the ability of a potential target company’s personnel, vendors and service providers to negotiate and consummate an initial Business Combination in a timely manner. The Company’s ability to consummate an initial Business Combination may also be dependent on the ability to raise additional equity and debt financing, which may be impacted by the COVID-19 outbreak and the resulting market downturn. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Additionally, as a result of the military action commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, the Company’s ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate a Business Combination are not yet determinable. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC (as defined below). Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Form 10-K filed by the Company with the SEC on April 15, 2022. Emerging Growth Company The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, ( the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section 102(b)(1) of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents As of June 30, 2022 and December 31, 2021, the Company had $552,084 and $336,852 in cash. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash and cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021. Marketable Securities Held in Trust Account At June 30, 2022 and December 31, 2021, the assets held in the Trust Account were held in institutional money market mutual funds and cash. The Company’s investments held in the Trust Account are classified as trading securities. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 5,750,000 shares of Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets. All of the 5,750,000 Class A ordinary share sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary share subject to redemption to be classified outside of permanent equity. The Class A ordinary share is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary share resulted in charges against additional paid-in capital and accumulated deficit. As of June 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected on the balance sheet are reconciled in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2022 ​ 2021 Gross proceeds from IPO ​ $ 57,500,000 $ 57,500,000 Less: ​ ​ ​ ​ ​ ​ Proceeds allocated to Warrants ​ (136,971) ​ ​ (136,971) Ordinary share issuance costs ​ (4,120,737) ​ ​ (4,120,737) Plus: ​ ​ ​ ​ Accretion of carrying value to redemption value ​ 4,257,708 ​ ​ 4,257,708 Additional amount deposited into trust ​ 1,725,000 ​ ​ 575,000 Remeasurement of Class A ordinary shares subject to possible redemption ​ ​ 83,721 ​ ​ 3,580 Contingently redeemable ordinary shares ​ $ 59,308,721 ​ $ 58,078,580 ​ On March 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to July 12, 2022. On June 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from July 12, 2022 to October 12, 2022. Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO and were charged to shareholders’ equity upon the completion of the IPO, while the offering costs attributable to private placement warrants are immaterial and not recorded. Accordingly, as of June 30, 2022, offering costs in the aggregate of $4,120,737 have been charged to shareholders’ equity (consisting of $1,150,000 of underwriting fee, $2,012,500 of deferred underwriting fee, and $496,269 of other offering costs, and $461,968 of fair value of 57,500 representative’s ordinary shares). Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. Income Taxes ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement’s recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the British Virgin Islands. In accordance with British Virgin Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are recorded at fair value on the grant date and re- valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Financial Accounting Standards Board (“FASB”) ASC 470-20, Debt with Conversion and Other Options addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between Class A ordinary shares and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then the Class A ordinary shares. The Company accounts for the private placement warrants as warrant liabilities due to certain features contained in the warrant agreements that give rise to liability treatment. The public warrants are treated as equity as they do not meet the definition of a warrant liability. Net Loss Per Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 3,021,250 potential common shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and six months ended June 30, 2022, because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for each class of ordinary shares: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the period from ​ ​ For the three months ended ​ For the three months ended ​ For the six months ended ​ January 8, 2021 (Inception) to ​ ​ June 30, 2022 ​ June 30, 2021 ​ June 30, 2022 ​ June 30, 2021 ​ ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Class A Class A Class A Class A Class A Class A Class A Class A Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allocation of net loss ​ (339,504) ​ (105,541) ​ (48,372) ​ (16,949) ​ (457,752) ​ (142,301) ​ (43,282) ​ (25,764) Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average shares outstanding ​ 5,750,000 ​ 1,787,500 ​ 4,967,033 ​ 1,740,357 ​ 5,750,000 ​ 1,787,500 ​ 2,612,717 ​ 1,555,260 Basic and diluted net loss per share ​ (0.06) ​ (0.06) ​ (0.01) ​ (0.01) ​ (0.08) ​ (0.08) ​ (0.02) ​ (0.02) ​ Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

Initial Public Offering

Initial Public Offering	6 Months Ended
	Jun. 30, 2022
Initial Public Offering.
Initial Public Offering	Note 3 — Initial Public Offering Pursuant to the IPO, the Company sold 5,000,000 Units, (at a price of $10.00 per Unit. Each Unit consists of one Class A ordinary share, one-half one-tenth On April 15, 2021, the underwriter fully exercised their over-allotment option with respect to the 750,000 option units resulting in gross proceeds of $7,500,000.

Private Placement

Private Placement	6 Months Ended
	Jun. 30, 2022
Private Placement.
Private Placement	Note 4 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 270,000 Private Placement Units at a price of $10.00 per unit ($2,700,000 in the aggregate), Each Private Placement Unit are identical to the Units sold in the IPO, except as described below. There are no redemption rights or liquidating distributions from the Trust Account with respect to the founder shares, private placement shares, private placement warrants or private placement rights. The warrants and rights will expire worthless if the Company does not consummate a Business Combination within the allotted 12-month period (or up to 18 months from the completion of the IPO if the Company extends the period of time to consummate a Business Combination by the full amount of time). A portion of the purchase price of the Private Placement Units was added to the proceeds from this offering to be held in the Trust Account. Simultaneously with the fully exercise of over-allotment option, the Sponsor purchased an aggregate of 22,500 Private Placement Units resulting in gross proceeds of $225,000.

Fair Value of Warrant Liabiliti

Fair Value of Warrant Liabilities	6 Months Ended
	Jun. 30, 2022
Fair Value of Warrant Liabilities
Fair Value of Warrant Liabilities	Note 5 — Fair Value of Warrant Liabilities Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies is as follows: Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity’s own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis as of June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 Total Asset: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketable securities held in Trust Account ​ $ 59,308,721 ​ $ — ​ $ — ​ $ 59,308,721 Total Asset ​ $ 59,308,721 ​ $ — ​ $ — ​ $ 59,308,721 Liability: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability ​ $ — ​ $ — ​ $ 15,443 ​ $ 15,443 Total Liability ​ $ — ​ $ — ​ $ 15,443 ​ $ 15,443 ​ The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 Total Asset: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketable securities held in Trust Account ​ $ 58,078,580 ​ $ — ​ $ — ​ $ 58,078,580 Total Asset ​ $ 58,078,580 ​ $ — ​ $ — ​ $ 58,078,580 Liability: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability ​ $ — ​ $ — ​ $ 52,151 ​ $ 52,151 Total Liability ​ $ — ​ $ — ​ $ 52,151 ​ $ 52,151 ​ The estimated fair value of the warrants is determined using Level 3 inputs. Inherent in a Monte-Carlo simulation model are assumptions related to expected stock-price volatility (pre-merger and post-merger), expected term, dividend yield and risk-free interest rate. The Company estimates the volatility of its ordinary shares based on management’s understanding of the volatility associated with instruments of other similar entities. The risk-free interest rate is based on the U.S. Treasury Constant Maturity similar to the expected remaining life of the warrants. The expected life of the warrants is simulated based on management assumptions regarding the timing and likelihood of completing a Business Combination. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. Once the warrants become exercisable, the Company may redeem the outstanding warrants when the price per Class A ordinary shares equals or exceeds $18.00. The assumptions used in calculating the estimated fair values at the end of the reporting period represent the Company’s best estimate. However, inherent uncertainties are involved. If factors or assumptions change, the estimated fair values could be materially different. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at June 30, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ April 12, ​ December 31, ​ ​ June 30, Inputs 2021 2021 ​ 2022 Exercise price ​ $ 11.50 ​ $ 11.50 ​ $ 11.50 ​ Stock price ​ $ 8.07 ​ $ 9.99 ​ $ 10.19 ​ Volatility ​ ​ 24.4 % ​ 7.1 % ​ 9.5 % Expected term of the warrants ​ ​ 5.69 ​ ​ 5.35 ​ 5.19 ​ Risk-free rate ​ ​ 1.03 ​ ​ 1.29 % ​ 3.01 % Dividend yield ​ ​ — ​ ​ — ​ — ​ ​ The following table sets forth a summary of the changes in the fair value of the warrant liability for the six months ended June 30, 2022: ​ ​ ​ ​ ​ ​ Warrant ​ Liability Fair value as of December 31, 2021 ​ $ 52,151 Change in fair value of warrant liability ​ ​ (30,096) Fair value as of March 31, 2022 ​ $ 22,055 Change in fair value of warrant liability ​ ​ (6,612) Fair value as of June 30, 2022 ​ $ 15,443 ​ The following table sets forth a summary of the changes in the fair value of the warrant liability for the period from January 8, 2021 (inception) to June 30, 2021: ​ ​ ​ ​ ​ ​ Warrant ​ ​ Liability Fair value as of January 8, 2021 (inception) and March 31, 2021 ​ $ — Initial fair value of warrant liability upon issuance at IPO ​ 126,435 Initial fair value of warrant liability upon the exercise of over-allotment option ​ 10,536 Change in fair value of warrant liability ​ (61,263) Fair value as of June 30, 2021 ​ $ 75,708 ​

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	Note 6 — Related Party Transactions Founder Shares On January 13, 2021, the Company issued 1,437,500 Founder Shares for an aggregate purchase price of $25,001. Up to 187,500 founder shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters’ over-allotment option is exercised. On April 15, 2021, the underwriter exercised the full overallotment option and therefore the 187,500 founder shares are no longer subject to forfeiture (See Note 8). The Sponsor, officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed (A) to waive their redemption rights with respect to their founder shares and public shares in connection with the completion of the initial Business Combination and (B) to waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within such time period and (iv) the founder shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, as described in the amended and restated memorandum and articles of association. If the Company submits the initial Business Combination to the public shareholders for a vote, the Sponsor, officers and directors have agreed (and their permitted transferees will agree) to vote their founder shares and any public shares purchased during or after the IPO in favor of the initial Business Combination. Promissory Note - Related Party On January 13, 2021, the Sponsor agreed to loan the Company up to $200,000 to be used for a portion of the expenses of the IPO. These loans are non-interest bearing, unsecured and are due at the closing of the IPO. The Company had borrowed $200,000 under the promissory note and fully repaid as of August 24, 2021. As of June 30, 2022 and December 31, 2021, the Promissory Note was terminated. Working Capital Loans In addition, in order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,150,000 of such Working Capital Loans may be convertible into warrants of the post-Business Combination company at a price of $10.00 per unit at the option of the lender. Such units would be identical to the Private Placement Units. As of June 30, 2022 and December 31, 2021, the Company had no borrowings under the Working Capital Loans. Extension Loan The Company has until April 12, 2022 (12 months from the closing of the IPO) to consummate an initial Business Combination. The Company could extend the period of time to consummate a Business Combination up to two times, each by an additional three months (for a total of up to 18 months to complete a Business Combination). Pursuant to the terms of the amended and restated memorandum and articles of association and the trust agreement to be entered into between the Company and Continental Stock Transfer & Trust Company on the date of the IPO, in order to extend the time available for the Company to consummate the initial Business Combination, the Sponsor or its affiliates or designees, upon ten days advance notice prior to the applicable deadline, must deposit into the Trust Account $575,000 ($0.10 per share) on or prior to the date of the applicable deadline, for each three month extension (or up to an aggregate of $1,150,000), or $0.20 per share if the Company extends for the full six months). Any such payments would be made in the form of a loan. Any such loans will be non-interest bearing and payable upon the consummation of the initial Business Combination. If the Company completes the initial Business Combination, it will repay such loaned amounts out of the proceeds of the Trust Account released to the Company. Up to $1,150,000 of such loans may be convertible into units at a price of $10.00 per unit at the option of the lender. If the Company does not complete a Business Combination, the Company will not repay such loans. Furthermore, the letter agreement with the initial shareholders contains a provision pursuant to which the Sponsor has agreed to waive its right to be repaid for such loans out of the funds held in the Trust Account in the event that the Company does not complete a Business Combination. The Sponsor and its affiliates or designees are not obligated to fund the Trust Account to extend the time for the Company to complete the initial Business Combination. On March 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to July 12, 2022. On June 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from July 12, 2022 to October 12, 2022. Administrative Support Agreement Commencing on the date of the IPO, the Company will pay the Sponsor $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. For the three and six months ended June 30, 2022, the Company incurred $30,000 and $60,000 in expenses in connection with such services. For the period from April 7, 2021 (“Effective Date”) through June 30, 2021, the Company incurred $26,333 in expenses in connection with such services.

Promissory Note - MMV

Promissory Note - MMV	6 Months Ended
	Jun. 30, 2022
Promissory Note - MMW
Promissory Note - MMW	Note 7 — Promissory Note - MMV On January 6, 2022, each of the parties to the Merger Agreement and Avatar Group Holdings Limited entered into a First Amendment to the Merger Agreement (the “Amendment”). Under the Amendment, MMV agrees to make to Company, and the Company agrees to borrow from MMV three tranches of non-interest bearing loans in the aggregate principal amount of $2,750,000, all of which shall become repayable upon closing of the Business Combination, or if the Company, Model Performance Mini Corp. and Model Performance Mini Sub Corp. materially breach the Merger Agreement or the Amendment and such breach has not been cured within fifteen (15) days after the Company’s receipt of such notice containing the details of breach. On January 10, 2022, March 21, 2022, June 21, 2022 and June 29, 2022, the Company received loans for an aggregate of $2,459,975, from the target company, MMV.

Commitments & Contingencies

Commitments & Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments & Contingencies
Commitments & Contingencies	Note 8 — Commitments & Contingencies Registration Rights The holders of founder shares, Private Placement Units, shares being issued to the underwriters of the IPO, and units that may be issued on conversion of Working Capital Loans (and in each case holders of their component securities, as applicable) will be entitled to registration rights pursuant to a registration rights agreement signed prior to or on the effective date of the IPO requiring the Company to register such securities for resale (in the case of the founder shares, only after conversion to the Company’s Class A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. Underwriting Agreement The Company granted the underwriter a 45-day option from April 12, 2021 to purchase up to 750,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting fees and commissions. On April 15, 2021, the underwriter fully exercised the over-allotment option. On April 12, 2021, the Company paid a fixed underwriting fee of $1,000,000. On April 15, an additional of $150,000 underwriting fee was paid as a result of the fully exercise of over-allotment option. Additionally, a deferred underwriting fee of $2,012,500, will be payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes an initial Business Combination, subject to the terms of the underwriting agreement. Representative’s Ordinary Shares The Company has issued to Maxim Partners LLC and/or its designees, 57,500 ordinary shares upon the consummation of IPO and the exercise of the over-allotment option, the fair value of which is $461,968 using the Monte-Carlo simulation model. The fair value of the representative’s ordinary shares granted to Maxim was estimated as of the date of grant using the following assumptions: (1) expected volatility of 14%, (2) risk-free interest rate of 0.05% and (3) fair value per ordinary share of $8.69. The value of the Representative Shares had been recorded as deferred offering costs and additional paid-in capital upon Underwriter’s completion of the IPO services for which it received the Representative Shares as compensation. The deferred offering costs were included in the total offering costs that were allocated among public ordinary shares and warrants upon IPO. Maxim has agreed not to transfer, assign or sell any such shares until the completion of the initial Business Combination. In addition, Maxim has agreed (i) to waive its redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive its rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete the initial Business Combination within the Combination Period. The shares have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the date of the effectiveness of the registration statement pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities by any person for a period of 180 days immediately following the effective date of the registration statement, nor may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the commencement of sales in the IPO, except to any underwriter and selected dealer participating in the offering and their officers, partners, registered persons or affiliates. Right of First Refusal For a period beginning on the closing of the IPO and ending 12 months from the closing of a Business Combination, the Company has granted Maxim a right of first refusal to act as lead-left book running manager and lead left placement agent for any and all future private or public equity, equity-linked, convertible and debt offerings during such period. In accordance with FINRA Rule 5110(g)(6)(A), such right of first refusal shall not have a duration of more than three years from the commencement of sales in the IPO.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2022
Shareholders' Equity
Shareholders' Equity	Note 9 — Shareholders’ Deficit Preference Shares — Class A Ordinary Shares Class B Ordinary Shares Warrants In addition, if (x) the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s initial shareholders or their affiliates, without taking into account any founder shares held by such shareholders or their affiliates, as applicable, prior to such issuance (the “Newly Issued Price”)), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for funding the initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price shall be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described in the section “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The warrants will become exercisable on the later of 12 months from the closing of the IPO and 30 days after the completion of its initial Business Combination and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. The Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use best efforts to file, and within 60 business days following the initial Business Combination to have declared effective, a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. No warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the Class A ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such Class A ordinary shares. Notwithstanding the foregoing, if a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective within a specified period following the consummation of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. Once the public warrants become exercisable, the Company may redeem the public warrants: ● in whole and not in part; ● at a price of $0.01 per public warrant; ● upon not less than 30 days ‘prior written notice of redemption to each warrant holder and ● if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30 -trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted). The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A ordinary shares may fall below the $18.00 redemption trigger price as well as the $11.50 warrant exercise price after the redemption notice is issued. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise his, her or its warrant to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” the management will consider, among other factors, the Company’s cash position, the number of warrants that are outstanding and the dilutive effect on the Company’s shareholders of issuing the maximum number of Class A ordinary shares issuable upon the exercise of the warrants. If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If the management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of Class A ordinary shares to be received upon exercise of the warrants, including the “fair market value” in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. The Company believes this feature is an attractive option to the Company if it does not need the cash from the exercise of the warrants after the initial Business Combination. If the Company calls the warrants for redemption and the management does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their private placement warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis. If the number of issued and outstanding Class A ordinary shares is increased by a capitalization payable in Class A ordinary shares, or by a sub-division of Class A ordinary shares or other similar event, then, on the effective date of such capitalization, sub-division or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the issued and outstanding Class A ordinary shares. A rights offering to holders of Class A ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the fair market value will be deemed a capitalization of a number of Class A ordinary shares equal to the product of (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A ordinary shares) multiplied by (ii) one (1) minus the quotient of (x) the price per Class A ordinary share paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for Class A ordinary shares, in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted average price of Class A ordinary shares as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the Class A ordinary shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. Rights Each holder of a right will receive one-tenth 1/10 right (without paying any additional consideration) upon consummation of the Business Combination. More specifically, the right holder will be required to indicate its election to convert the rights into underlying shares as well as to return the original rights certificates to the Company. If the Company is unable to complete an initial Business Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. As soon as practicable upon the consummation of the initial Business Combination, the Company will direct registered holders of the rights to return their rights to the rights agent. Upon receipt of the rights, the rights agent will issue to the registered holder of such rights the number of full Class A ordinary shares to which it is entitled. The Company will notify registered holders of the rights to deliver their rights to the rights agent promptly upon consummation of such Business Combination and have been informed by the rights agent that the process of exchanging their rights for Class A ordinary shares should take no more than a matter of days. The foregoing exchange of rights is solely ministerial in nature and is not intended to provide the Company with any means of avoiding the Company’s obligation to issue the shares underlying the rights upon consummation of the initial Business Combination. Other than confirming that the rights delivered by a registered holder are valid, the Company will have no ability to avoid delivery of the shares underlying the rights. Nevertheless, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of an initial Business Combination. The shares issuable upon conversion of the rights will be freely tradable (except to the extent held by affiliates of the Company’s). The Company will not issue fractional shares upon conversion of the rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of British Virgin Island’s law. As a result, you must hold rights in multiples of 10 in order to receive shares for all of the investors’ rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company liquidates the funds held in the Trust Account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of an initial Business Combination. Accordingly, the rights may expire worthless.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events
Subsequent Events	Note 10 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC (as defined below). Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Form 10-K filed by the Company with the SEC on April 15, 2022.
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, ( the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, Section 102(b)(1) of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates	Use of Estimates The preparation of these financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents As of June 30, 2022 and December 31, 2021, the Company had $552,084 and $336,852 in cash. The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash and cash equivalents. The Company did not have any cash equivalents as of June 30, 2022 and December 31, 2021.
Marketable Securities Held in Trust Account	Marketable Securities Held in Trust Account At June 30, 2022 and December 31, 2021, the assets held in the Trust Account were held in institutional money market mutual funds and cash. The Company’s investments held in the Trust Account are classified as trading securities.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts.
Class A Ordinary Shares Subject to Possible Redemption	Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, at June 30, 2022 and December 31, 2021, 5,750,000 shares of Class A ordinary shares subject to possible redemption is presented at redemption value as temporary equity, outside of the shareholders’ equity section of the Company’s balance sheets. All of the 5,750,000 Class A ordinary share sold as part of the Units in the IPO contain a redemption feature which allows for the redemption of such public shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Company’s certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require ordinary share subject to redemption to be classified outside of permanent equity. The Class A ordinary share is subject to SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or to recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company recognizes changes in redemption value immediately as they occur. Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary share resulted in charges against additional paid-in capital and accumulated deficit. As of June 30, 2022 and December 31, 2021, the Class A ordinary shares subject to possible redemption reflected on the balance sheet are reconciled in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2022 ​ 2021 Gross proceeds from IPO ​ $ 57,500,000 $ 57,500,000 Less: ​ ​ ​ ​ ​ ​ Proceeds allocated to Warrants ​ (136,971) ​ ​ (136,971) Ordinary share issuance costs ​ (4,120,737) ​ ​ (4,120,737) Plus: ​ ​ ​ ​ Accretion of carrying value to redemption value ​ 4,257,708 ​ ​ 4,257,708 Additional amount deposited into trust ​ 1,725,000 ​ ​ 575,000 Remeasurement of Class A ordinary shares subject to possible redemption ​ ​ 83,721 ​ ​ 3,580 Contingently redeemable ordinary shares ​ $ 59,308,721 ​ $ 58,078,580 ​ On March 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from April 12, 2022 to July 12, 2022. On June 29, 2022, using the loan amount received to date, the Company deposited into the Company’s trust account an additional $575,000 (representing $0.10 per Class A ordinary share) to extend the Combination Period from July 12, 2022 to October 12, 2022.
Offering Costs	Offering Costs The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A – “Expenses of Offering”. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the IPO and were charged to shareholders’ equity upon the completion of the IPO, while the offering costs attributable to private placement warrants are immaterial and not recorded. Accordingly, as of June 30, 2022, offering costs in the aggregate of $4,120,737 have been charged to shareholders’ equity (consisting of $1,150,000 of underwriting fee, $2,012,500 of deferred underwriting fee, and $496,269 of other offering costs, and $461,968 of fair value of 57,500 representative’s ordinary shares).
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Income Taxes	Income Taxes ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement’s recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the British Virgin Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the British Virgin Islands. In accordance with British Virgin Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s unaudited condensed consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.
Warrant Liability	Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. Derivative instruments are recorded at fair value on the grant date and re- valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Financial Accounting Standards Board (“FASB”) ASC 470-20, Debt with Conversion and Other Options addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between Class A ordinary shares and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then the Class A ordinary shares. The Company accounts for the private placement warrants as warrant liabilities due to certain features contained in the warrant agreements that give rise to liability treatment. The public warrants are treated as equity as they do not meet the definition of a warrant liability.
Net Loss Per Share	Net Loss Per Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Earnings and losses are shared pro rata between the two classes of shares. The 3,021,250 potential common shares for outstanding warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three and six months ended June 30, 2022, because the warrants are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for each class of ordinary shares: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the period from ​ ​ For the three months ended ​ For the three months ended ​ For the six months ended ​ January 8, 2021 (Inception) to ​ ​ June 30, 2022 ​ June 30, 2021 ​ June 30, 2022 ​ June 30, 2021 ​ ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Class A Class A Class A Class A Class A Class A Class A Class A Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allocation of net loss ​ (339,504) ​ (105,541) ​ (48,372) ​ (16,949) ​ (457,752) ​ (142,301) ​ (43,282) ​ (25,764) Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average shares outstanding ​ 5,750,000 ​ 1,787,500 ​ 4,967,033 ​ 1,740,357 ​ 5,750,000 ​ 1,787,500 ​ 2,612,717 ​ 1,555,260 Basic and diluted net loss per share ​ (0.06) ​ (0.06) ​ (0.01) ​ (0.01) ​ (0.08) ​ (0.08) ​ (0.02) ​ (0.02)
Recent Accounting Standards	Recent Accounting Standards Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s unaudited condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Schedule of reconciliation of Class A ordinary shares subject to possible redemption reflected on the balance sheet	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, December 31, ​ ​ 2022 ​ 2021 Gross proceeds from IPO ​ $ 57,500,000 $ 57,500,000 Less: ​ ​ ​ ​ ​ ​ Proceeds allocated to Warrants ​ (136,971) ​ ​ (136,971) Ordinary share issuance costs ​ (4,120,737) ​ ​ (4,120,737) Plus: ​ ​ ​ ​ Accretion of carrying value to redemption value ​ 4,257,708 ​ ​ 4,257,708 Additional amount deposited into trust ​ 1,725,000 ​ ​ 575,000 Remeasurement of Class A ordinary shares subject to possible redemption ​ ​ 83,721 ​ ​ 3,580 Contingently redeemable ordinary shares ​ $ 59,308,721 ​ $ 58,078,580
Reconciliation of Net Loss per Common Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the period from ​ ​ For the three months ended ​ For the three months ended ​ For the six months ended ​ January 8, 2021 (Inception) to ​ ​ June 30, 2022 ​ June 30, 2021 ​ June 30, 2022 ​ June 30, 2021 ​ ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ ​ Class B and ​ ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Redeemable ​ Non-redeemable ​ Class A Class A Class A Class A Class A Class A Class A Class A Numerator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allocation of net loss ​ (339,504) ​ (105,541) ​ (48,372) ​ (16,949) ​ (457,752) ​ (142,301) ​ (43,282) ​ (25,764) Denominator: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average shares outstanding ​ 5,750,000 ​ 1,787,500 ​ 4,967,033 ​ 1,740,357 ​ 5,750,000 ​ 1,787,500 ​ 2,612,717 ​ 1,555,260 Basic and diluted net loss per share ​ (0.06) ​ (0.06) ​ (0.01) ​ (0.01) ​ (0.08) ​ (0.08) ​ (0.02) ​ (0.02)

Fair Value of Warrant Liabili_2

Fair Value of Warrant Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value of Warrant Liabilities
Schedule of fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis	The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis as of June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 Total Asset: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketable securities held in Trust Account ​ $ 59,308,721 ​ $ — ​ $ — ​ $ 59,308,721 Total Asset ​ $ 59,308,721 ​ $ — ​ $ — ​ $ 59,308,721 Liability: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability ​ $ — ​ $ — ​ $ 15,443 ​ $ 15,443 Total Liability ​ $ — ​ $ — ​ $ 15,443 ​ $ 15,443 ​ The following presents the Company’s fair value hierarchy for those assets and liabilities measured at fair value on non-recurring basis as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 Total Asset: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Marketable securities held in Trust Account ​ $ 58,078,580 ​ $ — ​ $ — ​ $ 58,078,580 Total Asset ​ $ 58,078,580 ​ $ — ​ $ — ​ $ 58,078,580 Liability: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability ​ $ — ​ $ — ​ $ 52,151 ​ $ 52,151 Total Liability ​ $ — ​ $ — ​ $ 52,151 ​ $ 52,151
Schedule of quantitative information regarding Level 3 fair value measurements inputs	The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at June 30, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ April 12, ​ December 31, ​ ​ June 30, Inputs 2021 2021 ​ 2022 Exercise price ​ $ 11.50 ​ $ 11.50 ​ $ 11.50 ​ Stock price ​ $ 8.07 ​ $ 9.99 ​ $ 10.19 ​ Volatility ​ ​ 24.4 % ​ 7.1 % ​ 9.5 % Expected term of the warrants ​ ​ 5.69 ​ ​ 5.35 ​ 5.19 ​ Risk-free rate ​ ​ 1.03 ​ ​ 1.29 % ​ 3.01 % Dividend yield ​ ​ — ​ ​ — ​ — ​
Schedule of change in the fair value of the warrant liabilities	The following table sets forth a summary of the changes in the fair value of the warrant liability for the six months ended June 30, 2022: ​ ​ ​ ​ ​ ​ Warrant ​ Liability Fair value as of December 31, 2021 ​ $ 52,151 Change in fair value of warrant liability ​ ​ (30,096) Fair value as of March 31, 2022 ​ $ 22,055 Change in fair value of warrant liability ​ ​ (6,612) Fair value as of June 30, 2022 ​ $ 15,443 ​ The following table sets forth a summary of the changes in the fair value of the warrant liability for the period from January 8, 2021 (inception) to June 30, 2021: ​ ​ ​ ​ ​ ​ Warrant ​ ​ Liability Fair value as of January 8, 2021 (inception) and March 31, 2021 ​ $ — Initial fair value of warrant liability upon issuance at IPO ​ 126,435 Initial fair value of warrant liability upon the exercise of over-allotment option ​ 10,536 Change in fair value of warrant liability ​ (61,263) Fair value as of June 30, 2021 ​ $ 75,708

Organization, Business Operat_2

Organization, Business Operation, Liquidation and Going Concern (Details)

3 Months Ended

6 Months Ended

Jun. 29, 2022 USD ($) $ / shares

Mar. 29, 2022 USD ($) $ / shares

Jan. 06, 2022 USD ($) tranche item

Aug. 24, 2021 USD ($)

Apr. 15, 2021 USD ($) shares

Apr. 12, 2021 USD ($) $ / shares shares

Jun. 30, 2021 $ / shares shares

Jun. 30, 2022 USD ($) item $ / shares shares

Jun. 30, 2021 USD ($) $ / shares

Jun. 21, 2022 USD ($)

Mar. 31, 2022 $ / shares

Mar. 21, 2022 USD ($)

Jan. 10, 2022 USD ($)

Dec. 31, 2021 USD ($)

Subsidiary, Sale of Stock [Line Items]

Condition for future business combination number of businesses minimum | item

1

Deposited into the Trust Account

$ 575,000

$ 575,000

Price per unit | $ / shares

$ 0.10

$ 0.10

Investment of cash into Trust Account

$ 575,000

$ 575,000

$ 1,150,000

$ 58,075,000

Class A ordinary share subject to possible redemption, per share | $ / shares

$ 0.10

$ 0.10

$ 10

$ 0.10

$ 10

$ 0.10

Proceeds from loan from related party

$ 2,459,975

$ 0

Transaction Costs

4,120,737

Underwriting fee

1,150,000

Deferred underwriting fee

2,012,500

Fair value of option exercised

461,968

Other offering costs

$ 496,269

Shares issued | shares

57,500

Cash

$ 552,084

$ 336,852

Working Capital

$ 2,098,688

Promissory Note - Related Party

Subsidiary, Sale of Stock [Line Items]

Proceeds from loan from related party

$ 200,000

Extension Loan

Subsidiary, Sale of Stock [Line Items]

Price per unit | $ / shares

$ 10

MMV Loans

Subsidiary, Sale of Stock [Line Items]

Number of tranches of non-interest bearing loans | tranche

3

Aggregate principal amount

$ 2,459,975

$ 2,750,000

$ 2,459,975

$ 2,459,975

$ 2,459,975

Maximum breach term

15 days

First Amendment to the Merger Agreement

Subsidiary, Sale of Stock [Line Items]

Number of new covenants | item

5

Aggregate principal amount

$ 10,000,000

Maximum breach term

15 days

Subscription Agreement

Subsidiary, Sale of Stock [Line Items]

Threshold period prior to the closing date of the Business Combination for covenant to procure equity financing

15 days

Committed PIPE Financing

$ 10,000,000

Additional PIPE Financing

$ 10,000,000

Private Placement Warrants

Subsidiary, Sale of Stock [Line Items]

Investments Maximum Maturity Term

180 days

Initial Public Offering

Subsidiary, Sale of Stock [Line Items]

Number of units sold | shares

5,000,000

Price per unit | $ / shares

$ 10

Proceeds from Issuance of units

$ 50,000,000

Private Placement

Subsidiary, Sale of Stock [Line Items]

Number of units sold | shares

22,500

270,000

270,000

Price per unit | $ / shares

$ 10

Proceeds from Issuance of units

$ 225,000

Threshold period for warrants and rights expiration if the entity does not consummate a Business Combination

12 months

Threshold period for warrants and rights expiration from completion of the Initial Public Offering

18 months

Private Placement | Private Placement Warrants

Subsidiary, Sale of Stock [Line Items]

Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)

100%

Threshold period for warrants and rights expiration if the entity does not consummate a Business Combination

12 months

Threshold period for warrants and rights expiration from completion of the Initial Public Offering

18 months

Private Placement | Private Placement Units

Subsidiary, Sale of Stock [Line Items]

Number of units sold | shares

270,000

Price per unit | $ / shares

$ 10

Threshold period for warrants and rights expiration if the entity does not consummate a Business Combination

12 months

Threshold period for warrants and rights expiration from completion of the Initial Public Offering

18 months

Over-allotment option

Subsidiary, Sale of Stock [Line Items]

Number of units sold | shares

750,000

22,500

Price per unit | $ / shares

$ 10.10

Proceeds from Issuance of units

$ 7,500,000

$ 58,075,000

Transaction Costs

4,120,737

Over-allotment option | Private Placement Units

Subsidiary, Sale of Stock [Line Items]

Number of units sold | shares

22,500

Note Warrant

Subsidiary, Sale of Stock [Line Items]

Proceeds from Issuance of units

$ 200,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)			3 Months Ended	6 Months Ended
	Jun. 29, 2022	Mar. 29, 2022	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents
Cash			$ 552,084	$ 552,084			$ 336,852
Investment of cash into Trust Account	$ 575,000	$ 575,000		$ 1,150,000	$ 58,075,000
Class A ordinary share subject to possible redemption, per share	$ 0.10	$ 0.10	$ 0.10	$ 0.10	$ 10	$ 0.10
Federal Depository Insurance Coverage				$ 250,000
Transaction Costs			$ 4,120,737	4,120,737
Underwriting fee			1,150,000	1,150,000
Deferred underwriting fee			2,012,500	2,012,500
Fair value of option exercised			$ 461,968	$ 461,968
Shares issued			57,500	57,500
Other offering costs			$ 496,269	$ 496,269
Unrecognized tax benefits			0	0			0
Unrecognized tax benefits accrued for interest and penalties			0	0			$ 0
Representative Shares
Cash and Cash Equivalents
Fair value of option exercised			$ 461,968	$ 461,968
Shares issued			57,500	57,500
Class A ordinary shares
Cash and Cash Equivalents
Anti-dilutive securities attributable to warrants (in shares)			3,021,250	3,021,250
Class A Common Stock Subject to Redemption
Cash and Cash Equivalents
Shares subject to possible redemption			5,750,000	5,750,000			5,750,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Ordinary share reflected on the balance sheet (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Summary of Significant Accounting Policies
Gross proceeds from IPO			$ 57,500,000		$ 57,500,000
Proceeds allocated to Warrants			(136,971)		(136,971)
Ordinary share issuance costs			(4,120,737)		(4,120,737)
Accretion of carrying value to redemption value		$ 4,257,708	4,257,708		4,257,708
Additional amount in deposited into trust ($10.10 per Unit-$10.00 per Unit)			1,725,000		575,000
Remeasurement of Class A ordinary shares subject to possible redemption			83,721		3,580
Accretion of interest income	$ (78,708)	$ (668)	(80,141)	$ (668)
Ordinary shares subject to possible redemption	$ 59,308,721		$ 59,308,721		$ 58,078,580
Shares subject to possible redemption, price per unit		$ 10.10		$ 10.10

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Reconciliation of Net Loss per Common Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Redeemable Class A Ordinary Shares
Allocation of net loss	$ (339,504)	$ (48,372)	$ (457,752)	$ (43,282)
Weighted average shares outstanding, Basic (in shares)	5,750,000	4,967,033	5,750,000	2,612,717
Weighted average shares outstanding, Diluted (in shares)	5,750,000	4,967,033	5,750,000	2,612,717
Basic net loss per share	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)
Diluted net loss per share	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)
Class B and Non-redeemable Class A
Allocation of net loss	$ (105,541)	$ (16,949)	$ (142,301)	$ (25,764)
Weighted average shares outstanding, Basic (in shares)	1,787,500	1,740,357	1,787,500	1,555,260
Weighted average shares outstanding, Diluted (in shares)	1,787,500	1,740,357	1,787,500	1,555,260
Basic net loss per share	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)
Diluted net loss per share	$ (0.06)	$ (0.01)	$ (0.08)	$ (0.02)

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($)			3 Months Ended
	Apr. 15, 2021	Apr. 12, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 29, 2022	Mar. 29, 2022
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit					$ 0.10	$ 0.10
Fractional warrants issued upon separation of Units		0
Number of share to be issued per share upon consummation of the initial Business Combination		0.1
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of units sold		5,000,000
Purchase price, per unit		$ 10
Number of shares in a unit		1
Number of warrants in a unit		0.5
Exercise price of warrants		$ 11.50
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Number of units sold	750,000		22,500
Purchase price, per unit				$ 10.10
Gross proceeds	$ 7,500,000		$ 225,000

Private Placement (Details)

Private Placement (Details) - USD ($)			3 Months Ended	6 Months Ended
	Apr. 15, 2021	Apr. 12, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 29, 2022	Mar. 29, 2022
Subsidiary, Sale of Stock [Line Items]
Price per unit					$ 0.10	$ 0.10
Over-allotment option
Subsidiary, Sale of Stock [Line Items]
Number of units sold	750,000		22,500
Price per unit				$ 10.10
Gross proceeds	$ 7,500,000		$ 225,000
Over-allotment option | Private Placement Units
Subsidiary, Sale of Stock [Line Items]
Number of units sold	22,500
Gross proceeds	$ 225,000
Private Placement
Subsidiary, Sale of Stock [Line Items]
Number of units sold	22,500		270,000	270,000
Price per unit				$ 10
Threshold period for warrants and rights expiration if the entity does not consummate a Business Combination		12 months
Threshold period for warrants and rights expiration from completion of the Initial Public Offering		18 months
Gross proceeds			$ 2,700,000
Private Placement | Private Placement Units
Subsidiary, Sale of Stock [Line Items]
Number of units sold		270,000
Price per unit		$ 10
Threshold period for warrants and rights expiration if the entity does not consummate a Business Combination				12 months
Threshold period for warrants and rights expiration from completion of the Initial Public Offering				18 months
Gross proceeds		$ 2,700,000

Fair Value of Warrant Liabili_3

Fair Value of Warrant Liabilities (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Assets:
Marketable securities held in Trust Account	$ 59,308,721	$ 58,078,580
Total Asset	59,308,721	58,078,580
Liability:
Warrant Liability	15,443	52,151
Total Liability	15,443	52,151
Level 1
Assets:
Marketable securities held in Trust Account	59,308,721	58,078,580
Total Asset	59,308,721	58,078,580
Liability:
Warrant Liability	0	0
Total Liability	0	0
Level 2
Assets:
Marketable securities held in Trust Account	0	0
Total Asset	0	0
Liability:
Warrant Liability	0	0
Total Liability	0	0
Level 3
Assets:
Marketable securities held in Trust Account	0	0
Total Asset	0	0
Liability:
Warrant Liability	15,443	52,151
Total Liability	$ 15,443	$ 52,151

Fair Value of Warrant Liabili_4

Fair Value of Warrant Liabilities - Level 3 Fair Value Measurements Inputs (Details) - Level 3	Jun. 30, 2022 Y $ / shares	Dec. 31, 2021 $ / shares Y	Apr. 12, 2021 $ / shares Y
Exercise price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, Measurement inputs	11.50	11.50	11.50
Stock price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, Measurement inputs	10.19	9.99	8.07
Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, Measurement inputs	9.5	7.1	24.4
Expected term of the warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, Measurement inputs | Y	5.19	5.35	5.69
Risk-free rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, Measurement inputs	3.01	1.29	1.03
Dividend yield
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, Measurement inputs	0	0	0

Fair Value of Warrant Liabili_5

Fair Value of Warrant Liabilities - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at beginning balance	$ 22,055	$ 52,151
Change in fair value of warrant liability	(6,612)	(30,096)	$ (61,263)
Fair value at ending balance	$ 15,443	$ 22,055	75,708
Initial Public Offering
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Initial fair value of warrant liability			126,435
Over-allotment option
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Initial fair value of warrant liability			$ 10,536

Related Party Transactions - Fo

Related Party Transactions - Founder Shares (Details) - USD ($)		3 Months Ended
	Jan. 13, 2021	Mar. 31, 2021	Apr. 15, 2021
Related Party Transaction [Line Items]
Aggregate purchase price		$ 25,001
Founder Shares | Sponsor
Related Party Transaction [Line Items]
Number of shares issued	1,437,500
Aggregate purchase price	$ 25,001
Maximum shares subject to forfeiture	187,500		187,500

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)

3 Months Ended

6 Months Ended

Jan. 06, 2022 USD ($) tranche

Aug. 24, 2021 USD ($)

Jun. 30, 2022 USD ($) $ / shares

Jun. 30, 2021 USD ($)

Jun. 30, 2022 USD ($) item $ / shares

Jun. 30, 2021 USD ($)

Jun. 29, 2022 USD ($) $ / shares

Jun. 21, 2022 USD ($)

Mar. 29, 2022 USD ($) $ / shares

Mar. 21, 2022 USD ($)

Jan. 10, 2022 USD ($)

Dec. 31, 2021 USD ($)

Jan. 13, 2021 USD ($)

Related Party Transaction [Line Items]

Proceeds from loan from related party

$ 2,459,975

$ 0

Deposited into the Trust Account

$ 575,000

$ 575,000

Price per unit | $ / shares

$ 0.10

$ 0.10

Working capital loans warrant

Related Party Transaction [Line Items]

Outstanding balance of related party note

$ 0

0

$ 0

Loan conversion agreement warrant

$ 1,150,000

$ 1,150,000

Price of warrant | $ / shares

$ 10

$ 10

Promissory Note - Related Party

Related Party Transaction [Line Items]

Maximum borrowing capacity of related party promissory note

$ 200,000

Proceeds from loan from related party

$ 200,000

Administrative Service Fee

Related Party Transaction [Line Items]

Expenses per month

$ 10,000

Expenses incurred and paid

$ 30,000

$ 26,333

$ 60,000

Extension Loan

Related Party Transaction [Line Items]

Threshold period from the closing of the Proposed Public Offering to consummate an initial Business Combination

12 months

Number of extension to consummate an initial Business Combination | item

2

Extension Term

3 months

Threshold period from the closing of the Proposed Public Offering to consummate an initial Business Combination after extension

18 months

Advance notice prior to the applicable deadline affiliates or designees must deposit into the Trust Account

10 days

Price per share | $ / shares

$ 0.10

$ 0.10

Loans that me be convertible into units

$ 1,150,000

$ 1,150,000

Price per unit | $ / shares

$ 10

$ 10

Extension Loan | if the Company Extends for Three Months [Member]

Related Party Transaction [Line Items]

Extension Term

3 months

Amount per extension, affiliates or designees must deposit into the Trust Account

$ 575,000

$ 575,000

Price per share | $ / shares

$ 0.10

$ 0.10

Extension Loan | if the Company Extends for Full Six Months [Member]

Related Party Transaction [Line Items]

Extension Term

6 months

Amount per extension, affiliates or designees must deposit into the Trust Account

$ 1,150,000

$ 1,150,000

Price per share | $ / shares

$ 0.20

$ 0.20

MMV Loans

Related Party Transaction [Line Items]

Number of tranches of non-interest bearing loans | tranche

3

Aggregate principal amount

$ 2,750,000

$ 2,459,975

$ 2,459,975

$ 2,459,975

$ 2,459,975

Maximum breach term

15 days

Promissory Note - MMV (Details)

Promissory Note - MMV (Details) - Promissory Note - MMW.	Jun. 29, 2022 USD ($)	Jun. 21, 2022 USD ($)	Mar. 21, 2022 USD ($)	Jan. 10, 2022 USD ($)	Jan. 06, 2022 USD ($) tranche
Promissory Note - MMW
Number of tranches of non-interest bearing loans | tranche					3
Aggregate principal amount					$ 2,750,000
Maximum breach term					15 days
Amount of loans recieved	$ 2,459,975	$ 2,459,975	$ 2,459,975	$ 2,459,975

Commitments & Contingencies (De

Commitments & Contingencies (Details) - USD ($)			3 Months Ended	6 Months Ended
	Apr. 15, 2021	Apr. 12, 2021	Jun. 30, 2021	Jun. 30, 2022
Loss Contingencies [Line Items]
Maximum number of demands for registration of securities				three demands
Underwriting fees				$ 1,150,000
Deferred underwriting fee payable.				$ 2,012,500
Subject To Lock-Up Period				180 days
Shares issued				57,500
Fair value of option exercised				$ 461,968
Underwriters Agreement
Loss Contingencies [Line Items]
Options To Granted Period				45 days
Number of units sold		750,000
Initial Public Offering
Loss Contingencies [Line Items]
Number of units sold		5,000,000
Initial Public Offering | Underwriters Agreement
Loss Contingencies [Line Items]
Underwriting fees		$ 1,000,000
Over-allotment option
Loss Contingencies [Line Items]
Number of units sold	750,000		22,500
Over-allotment option | Underwriters Agreement
Loss Contingencies [Line Items]
Underwriting fees	$ 150,000
Deferred underwriting fee payable.	$ 2,012,500
Maxim Partners LLC
Loss Contingencies [Line Items]
Shares issued				57,500
Expected volatility				14%
Risk free interest rate				0.05%
Fair value per ordinary share				$ 8.69
Maxim Partners LLC | Over-allotment option
Loss Contingencies [Line Items]
Fair value of option exercised				$ 461,968

Shareholders' Equity - Preferre

Shareholders' Equity - Preferred Stock Shares (Details) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Shareholders' Equity
Preferred shares, shares authorized	1,000,000	1,000,000
Preferred stock, par value, (per share)	$ 0	$ 0
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0

Shareholders' Equity - Common S

Shareholders' Equity - Common Stock Shares (Details) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Class A ordinary shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	100,000,000
Common shares, par value (in dollars per share)	$ 0
Common shares, shares issued (in shares)	350,000	350,000
Common shares, shares outstanding (in shares)	350,000	350,000
Class A Common Stock Subject to Redemption
Class of Stock [Line Items]
Common stock subject to possible redemption, shares	5,750,000	5,750,000
Class B ordinary shares
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	10,000,000
Common shares, par value (in dollars per share)	$ 0
Common shares, shares issued (in shares)	1,437,500	1,437,500
Common shares, shares outstanding (in shares)	1,437,500	1,437,500

Shareholders' Equity - Warrants

Shareholders' Equity - Warrants (Details)	6 Months Ended
	Jun. 30, 2022 D $ / shares shares
Class of Warrant or Right [Line Items]
Issue price per share	$ 9.20
Percentage of gross proceeds on total equity proceeds	60%
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)	115%
Trading days determining volume weighted average price	20 days
Stock price trigger for redemption of public warrants (in dollars per share)	$ 18
Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)	180%
Warrants exercisable term from the closing of the initial public offering	12 months
Warrants exercisable term after the completion of a business combination	30 days
Warrants expiration term	5 years
Period of filing registration statement after business combination	15 days
Maximum period after business combination in which to file registration statement	60 days
Number of trading days on which fair market value of shares is reported | D	10
Redemption price per public warrant (in dollars per share)	$ 0.01
Minimum threshold written notice period for redemption of public warrants	30 days
Warrant redemption condition minimum share price	$ 18
Trading days for redemption of public warrant | D	20
Threshold consecutive trading days for redemption of warrants | D	30
Number of rights per unit | shares	0.1
Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 11.50